Samsca - (15 mg; Tablet, Oral)

Generic Name	Tolvaptan	**Innovator**	Otsuka
Dosage	15 mg; Tablet, Oral	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	Less Than 5
Other ANDA developers	Less Than 5	**Tentative Approvals**	None
Final Approvals	Less Than 5	**Generic Launches**	Less Than 5
Indication	Indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Samsca - (60 mg; Tablet, Oral)

Generic Name	Tolvaptan	**Innovator**	Otsuka
Dosage	60 mg; Tablet, Oral	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	Less Than 5
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	Less Than 5	**Generic Launches**	Less Than 5
Indication	Indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Samsca - (30 mg; Tablet, Oral)

Generic Name	Tolvaptan	**Innovator**	Otsuka
Dosage	30 mg; Tablet, Oral	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	Less Than 5
Other ANDA developers	Less Than 5	**Tentative Approvals**	None
Final Approvals	Less Than 5	**Generic Launches**	Less Than 5
Indication	Indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.